Following the decision by the European Medicines Agency (EMA) in November to approve lecanemab for Alzheimer’s disease treatment, eanNews decided to explore the practical, ethical, and policy implications of this approval with one of the EAN’s resident experts.
We invited Prof. Sebastiaan Engelborghs, Co-Chair of the EAN Scientific Panel on Dementia & Cognitive Disorders, for a thorough and highly informative chat with EAN Communications Committee member Dr. Raphael Wurm about various issues surrounding the recent EMA decision.
Watch the video below, or on our Vimeo channel.
